Last reviewed · How we verify

NCT04496232

Strategies for Reducing Sperm DNA Fragmentation in ICSI Semen Samples: a Prospective Randomized Controlled Trial

Completed NA Last updated 9 August 2022
What this trial tests

NA trial testing PICSI in Male Infertility in 300 participants. Completed in 1 December 2021.

Timeline
1 August 2020
Primary endpoint
1 December 2021
1 December 2021

Quick facts

Lead sponsorGanin Fertility Center
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment300
Start date1 August 2020
Primary completion1 December 2021
Estimated completion1 December 2021
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Ganin Fertility Center

Who can join

Adults 18 to 50, any sex, with Male Infertility. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Comparing second ejaculate and physiological ICSI (PICSI) as strategies for improvement of abnormal sperm DNA fragmentation in patients undergoing ICSI.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of PICSI

Trials testing the same drug.

Other recruiting trials for Male Infertility

Currently open trials in the same condition.

Other Ganin Fertility Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04496232.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing